Empagliflozin led to promising weight loss outcomes in patients with prediabetes and diabetes, with the results being more prominent in men than in women.
Patients with overweight or obesity who used maridebart cafraglutide experienced significant weight loss at 1 year, according ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback